Jyong Biotech Ltd. Ordinary Shares (MENS)vsBeiGene, Ltd. (ONC)
MENS
Jyong Biotech Ltd. Ordinary Shares
$2.05
0.00%
HEALTHCARE · Cap: $163.46M
ONC
BeiGene, Ltd.
$317.00
+1.17%
HEALTHCARE · Cap: $33.06B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
MENS
Avoid17
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MENS.
Margin of Safety
+79.5%
Fair Value
$1717.18
Current Price
$317.00
$1400.18 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Trading at 8.1x book value
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MENS
The strongest argument for MENS centers on Debt/Equity.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : MENS
The primary concerns for MENS are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are Price/Book, EPS Growth, Return on Equity. A P/E of 120.4x leaves little room for execution misses.
Key Dynamics to Monitor
MENS profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (161M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (42/100 vs 17/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Jyong Biotech Ltd. Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Jyong Biotech Ltd. (ticker: MENS) is a forward-thinking biotechnology company dedicated to advancing therapeutic solutions for cancer and autoimmune diseases. Utilizing its expertise in genomics and molecular biology, the company has developed a robust pipeline of innovative treatments backed by a strong intellectual property portfolio. With strategic collaborations in the biopharmaceutical sector, Jyong Biotech aims to leverage emerging market opportunities while maintaining a focus on scientific rigor and patient-centered care, positioning itself as a significant contributor to the future of healthcare innovation.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?